Berenberg analyst Gaurav Goparaju downgraded PhenomeX (CELL) to Hold from Buy with a price target of $1, down from $8, citing Bruker’s (BRKR) plans to acquire the company. The firm cites the pending deal for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CELL: